Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $87.5 million.

  • Vanda Pharmaceuticals' Operating Expenses rose 4925.92% to $87.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 4591.32%. This contributed to the annual value of $239.4 million for FY2024, which is 1589.61% up from last year.
  • Vanda Pharmaceuticals' Operating Expenses amounted to $87.5 million in Q3 2025, which was up 4925.92% from $91.1 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Operating Expenses' 5-year high stood at $91.1 million during Q2 2025, with a 5-year trough of $44.8 million in Q3 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Operating Expenses had a median value of $59.4 million in 2021 and averaged $62.6 million.
  • In the last 5 years, Vanda Pharmaceuticals' Operating Expenses crashed by 2703.14% in 2023 and then skyrocketed by 6062.4% in 2025.
  • Vanda Pharmaceuticals' Operating Expenses (Quarter) stood at $59.4 million in 2021, then dropped by 2.58% to $57.9 million in 2022, then decreased by 9.49% to $52.4 million in 2023, then rose by 21.2% to $63.5 million in 2024, then soared by 37.94% to $87.5 million in 2025.
  • Its Operating Expenses was $87.5 million in Q3 2025, compared to $91.1 million in Q2 2025 and $91.1 million in Q1 2025.